HDAC6_GEMM · Development of a novel genetically engineered mouse model to study the role of HDAC6 in oncogenesis and metastasis of non-small cell lung cancer.
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2018-10-01 → 2021-09-30
- Финансиране от ЕС
- 248 063 €
- Участници
- 2
- Схема
- MSCA-IF
Линиите свързват координатора с партньорите.
Накратко на български
Ролята на протеина HDAC6 при развитието и разпространението на недребноклетъчния рак на белия дроб се изучава чрез генетично модифицирани мишки. Разбирането на тези механизми може да помогне за създаването на по-добри стратегии за лечение на това заболяване.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Development of a novel genetically engineered mouse model to study the role of HDAC6 in oncogenesis and metastasis of non-small cell lung cancer.
Problem/issue being addressed: In this project we are investigating a new treatment option for non-small cell lung cancer patients. NSCLC accounts for nearly 85% of all cases of lung cancer. Despite the discovery of novel targeted therapies there is still a poor prognosis for lung cancer due to drug resistance and tumor recurrence. Why is it important for society: In Europe lung cancer is the second most common cancer in men and the third most common cancer in women. Besides a high mortality rate, lung cancer also causes a considerable socio-economic burden estimated to be about 18.1 billion Euro per year. Approximately 70% of all newly diagnosed patients present with local advanced or metastatic disease, requiring systemic chemotherapy. This project offers the potential to provide new treatment options to help reduce the impact of this disease on society. What are the overall objectives: The overall research aim is to understand the molecular mechanisms of a protein called Histone Deacetylase 6 (HDAC6) in the oncogenesis and metastasis of NSCLC. Drugs to target this protein have been used for many years in the clinic for the treatment of various cancers. However, the exact role that HDAC6 plays in the development of cancer remains poorly understood. In this project we hope to unravel these exact roles and so help development good treatment strategies for the use of these drugs in the treatment of NSCLC.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Lung cancer is a leading cause of cancer deaths in Europe. Non small cell lung cancer (NSCLC) accounts for nearly 85% of all cases of lung cancer with a five year survival rate of 15%. Novel targeted therapies are urgently needed to overcome drug resistance and prevent tumour recurrence. The host supervisor carried out a small molecule screen to identify therapeutics for the treatment of drug-resistant NSCLC. A novel specific inhibitor of histone deacetylase 6 (HDAC6) was discovered. The molecular mechanisms of HDAC6's role in cancer is beginning to be elucidated however, this task is made difficult due to the lack of a specific inhibitor. The overall research aim of this proposal is to understand the molecular mechanisms of HDAC6 in the tumour initiation and progression of NSCLC. To do this, I will develop a unique state-of-the-art conditional genetic mouse model of NSCLC in which HDAC6 is knocked out. I will do this work in the laboratory of Prof. Wong at New York University, an expert in conditional genetic mouse models. I will study the role of HDAC6 on the immune-microenvironment of the lung tumours using multi-parameter flow cytometry and single cell RNA-sequencing. Upon re-integration to the host laboratory I will establish the HDAC6 knockout NSCLC mouse model. Lastly, I will assess the efficacy of the novel HDAC6 inhibitor on tumour progression compared to the mouse model. This project has the potential to contribute greatly to our understanding of the role of HDAC6 in NSCLC and lead to the discovery of targeted therapeutic. Through this prestigious fellowship I will diversify my research skill-set, I will gain international experience in a world-leading laboratory of NSCLC and I will be excellently positioned to develop my independent research career on return to Europe.
Оригинален текст от CORDIS (на английски).
Участници
- ROYAL COLLEGE OF SURGEONS IN IRELAND · DUBLIN 2КоординаторИрландия
- NEW YORK UNIVERSITY · NEW YORKСъединени щати
Връзки
Данни: CORDIS, © Европейски съюз